期刊
BIOCHEMICAL SOCIETY TRANSACTIONS
卷 45, 期 -, 页码 131-139出版社
PORTLAND PRESS LTD
DOI: 10.1042/BST20160262
关键词
-
资金
- Wellcome Trust [WTISSF121302]
- Oxford Martin School [LC0910-004]
- Oxford Parkinson's Disease Centre (OPDC) Monument Trust Discovery Award from Parkinson's UK, a charity registered in England and Wales [2581970]
- Oxford Parkinson's Disease Centre (OPDC) Monument Trust Discovery Award from Parkinson's UK, a charity registered in Scotland [SC037554]
- National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford
- NIHR Comprehensive Local Research Network
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- European Union Innovative Medicines Initiatives (EU IMI) StemBANCC [115439]
- European Union's Seventh Framework Programme (FP7/2007-2013)
- EFPIA companies
- Medical Research Council [MR/M024962/1] Funding Source: researchfish
- Parkinson's UK [J-0901, J-1403] Funding Source: researchfish
- MRC [MR/M024962/1] Funding Source: UKRI
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are found in familial and idiopathic cases of Parkinson's disease (PD), but are also associated with immune-related disorders, notably Crohn's disease and leprosy. Although the physiological function of LRRK2 protein remains largely elusive, increasing evidence suggests that it plays a role in innate immunity, a process that also has been implicated in neurodegenerative diseases, including PD. Innate immunity involves macrophages and microglia, in which endogenous LRRK2 expression is precisely regulated and expression is strongly up-regulated upon cell activation. This brief report discusses the current understanding of the involvement of LRRK2 in innate immunity particularly in relation to PD, critically examining its role in myeloid cells, particularly macrophages and microglia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据